Advertisement

Topics

AstraZeneca's breast cancer drug wins EU nod for first-line use

06:21 EDT 28 Jul 2017 | SmartBrief

AstraZeneca's Faslodex, or fulvestrant, has been approved by European regulators as a first-line treatment for postmenopausal -More

Original Article: AstraZeneca's breast cancer drug wins EU nod for first-line use

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's breast cancer drug wins EU nod for first-line use"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...